Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : PLRX save search
Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market to Exhibit Immense Growth at a CAGR of 4.9% by 2034 | DelveInsight
Published: 2024-04-03 (Crawled : 22:00) - prnewswire.com
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: 1.87%
H: 3.4%
C: -1.02%
fibrosis therapeutics growth market
Pliant Therapeutics to Participate in Upcoming Investor Events
Published: 2024-04-02 (Crawled : 12:00) - globenewswire.com
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: -0.62%
H: 1.17%
C: 1.17%
therapeutics
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
Published: 2024-03-27 (Crawled : 14:30) - globenewswire.com
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: 1.34%
H: 3.63%
C: 1.54%
conference international therapeutics
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: 0.0%
H: 6.88%
C: 4.2%
treatment fibrosis bexotegrast therapeutics
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors
Published: 2024-03-12 (Crawled : 17:00) - biospace.com/
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: 0.0%
H: 6.88%
C: 4.2%
MRKR | $4.425 5.42% 10K
|
Consumer Services
|
| O: -1.2%
H: 4.88%
C: 3.17%
therapeutics
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
Published: 2024-02-27 (Crawled : 21:00) - globenewswire.com
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: 4.59%
H: 0.0%
C: -7.67%
update therapeutics financial results
Pliant Therapeutics to Participate in Upcoming Investor Conferences
Published: 2024-02-26 (Crawled : 13:00) - globenewswire.com
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: -0.3%
H: 4.27%
C: 1.4%
therapeutics
Pliant Therapeutics to Participate in Upcoming Investor Events - February 7, 2024
Published: 2024-02-07 (Crawled : 15:00) - biospace.com/
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: 0.0%
H: 0.93%
C: -0.87%
therapeutics
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Published: 2024-02-04 (Crawled : 00:00) - globenewswire.com
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: -5.78%
liver positive fibrosis bexotegrast trial therapeutics
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-03 (Crawled : 13:00) - globenewswire.com
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: 0.28%
H: 3.44%
C: 0.28%
conference therapeutics
Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
Published: 2023-11-13 (Crawled : 22:00) - globenewswire.com
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: 4.05%
H: 0.6%
C: -1.5%
meeting liver therapeutics
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Published: 2023-11-09 (Crawled : 21:00) - globenewswire.com
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: 10.0%
H: 2.94%
C: -11.46%
update therapeutics financial results
Pliant Therapeutics to Participate in Upcoming Investor Conferences
Published: 2023-11-08 (Crawled : 13:00) - globenewswire.com
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: 0.76%
H: 0.0%
C: -4.93%
therapeutics
Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1
Published: 2023-11-06 (Crawled : 13:00) - globenewswire.com
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: -0.12%
H: 1.37%
C: -3.98%
pln-1010 cancer immunotherapy meeting therapeutics
Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
Published: 2023-10-31 (Crawled : 20:00) - globenewswire.com
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: -0.2%
H: 3.45%
C: 1.37%
cancer immunotherapy meeting therapeutics
Primary Sclerosing Cholangitis Market to Grow at a Tremendous CAGR of 17.2% During the Study Period (2019-2032) | DelveInsight
Published: 2023-10-31 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.94%
H: 2.55%
C: 2.55%
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: -4.18%
H: 0.49%
C: -0.02%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -2.76%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: -0.2%
H: 3.45%
C: 1.37%
CALT | $18.5 1.65% 1.62% 1.5K
|
Health Technology
|
| O: -2.27%
H: 2.01%
C: 0.44%
study market
Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
Published: 2023-10-19 (Crawled : 12:00) - globenewswire.com
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: -0.3%
H: 3.26%
C: 2.74%
meeting liver presentation bexotegrast therapeutics
Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer
Published: 2023-10-16 (Crawled : 20:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.4%
H: 0.0%
C: 0.0%
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: -0.78%
H: 2.85%
C: -3.27%
therapeutics
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: -1.24%
H: 0.0%
C: 0.0%
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: 7.89%
H: 11.25%
C: 5.98%
liver positive fibrosis bexotegrast trial therapeutics
Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis
Published: 2023-09-25 (Crawled : 20:00) - globenewswire.com
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: 7.89%
H: 11.25%
C: 5.98%
trial therapeutics
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.